Back to Journals » Lung Cancer: Targets and Therapy » Volume 14

ESCI
SJR OA
CiteScore
Impact Factor

Lung Cancer: Targets and Therapy

ISSN: 1179-2728


       

Archive: Volume 14, 2023

Commentary

Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

Nagasaka M, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:101-109

Published Date: 12 December 2023

Original Research

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer

Shi J, Li J, Wang H, Li X, Wang Q, Zhao C, Cheng L, Han R, Chen P, Guo H, Tang Z, Zhou C, Zhang Z, Wu F

Lung Cancer: Targets and Therapy 2023, 14:85-99

Published Date: 21 November 2023

Case report

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib

Wang L, Quan F, Guo Z, Lu Z, Yang D, Shi M

Lung Cancer: Targets and Therapy 2023, 14:79-84

Published Date: 9 October 2023

Perspectives

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:71-78

Published Date: 7 July 2023

Commentary

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?

Brazel D, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:63-69

Published Date: 23 June 2023

Commentary

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Lee AT, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:57-62

Published Date: 22 June 2023

Original Research

Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD

Lung Cancer: Targets and Therapy 2023, 14:47-55

Published Date: 19 May 2023

Commentary

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

Lee ATM, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:41-46

Published Date: 25 April 2023

Commentary

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Brazel D, Kim J, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:31-39

Published Date: 20 April 2023

Commentary

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code

Zhang SS, Lee A, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:27-30

Published Date: 19 April 2023

Review

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A

Lung Cancer: Targets and Therapy 2023, 14:11-25

Published Date: 3 February 2023

Review

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Brazel D, Ou SI, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:1-9

Published Date: 5 January 2023